Argenx Se (ARGX) was Downgraded to a Hold Rating at Kepler Capital

By Jason Carr

Argenx Se (ARGXResearch Report) received a Hold rating and a EUR220.00 price target from Kepler Capital analyst Damien Choplain on March 5. The company’s shares closed last Friday at $289.75.

According to TipRanks.com, Choplain is a 4-star analyst with an average return of 11.2% and a 39.5% success rate. Choplain covers the Healthcare sector, focusing on stocks such as Innate Pharma, Pharnext SA, and Galapagos.

Currently, the analyst consensus on Argenx Se is a Moderate Buy with an average price target of $335.01, implying a 13.4% upside from current levels. In a report issued on March 5, H.C. Wainwright also reiterated a Hold rating on the stock with a $320.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $382.15 and a one-year low of $103.75. Currently, Argenx Se has an average volume of 195.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.